Sector News

GSK CEO Witty’s pay whacked as U.K.’s largest drugmaker struggles to right itself

February 27, 2015
Life sciences
2014 was a tough year for GlaxoSmithKline. Its revenues and profits were off significantly. Its operating profit was off nearly 50% in pounds–and, as it turns out, so was CEO Andrew Witty’s pay. In fact he took a 46% whack to his compensation.
 
According to the drugmaker’s annual report, Witty’s total compensation was about £3.9 million, down from £7.2 million last year. His salary was up slightly but his bonus was cut 51% to £917,000 ($1.4 million from $2.9 million), the report shows.
 
“The vast majority of the chief executive officer’s remuneration is based on meeting stretching performance targets,” Glaxo spokesman Simon Steel told Bloomberg in an email. “The board recognized the challenging year the group has faced but it also recognized the good progress management has made.”
 
Nicholas Turner, an analyst with Mirabaud Securities in London, phrased it more bluntly. “You could read it as a message from the board that he’s underperforming,” he told Bloomberg.
 
Much of the problem was the hit that its top-selling drug, asthma treatment Advair, took in the U.S., down 10% last year as Express Scripts and CVS cut it from their formularies. That left patients to pay out of pocket for the product or switch to an approved alternative, and the numbers show many did the latter. Both pharmacy benefits managers have returned Advair to their lists for this year but only after GSK offered up enough in discounts to suit them.
 
As unpleasant as a big cut in pay may be, Witty at least kept his job while others did not. Earlier this month, U.S. chief Deirdre Connelly exited. Today, it was announced that Chairman Christopher Gent will leave in May instead of September as originally planned. He is being replaced by Sir Philip Hampton, who is now chairman of the Royal Bank of Scotland.
 
The pain has been felt deeply in the trenches as well. In October, GSK announced it would slice out $1.6 billion in costs to deal with the Advair weakness and two months later said it would ax 900 jobs in North Carolina, both in R&D and commercial operations.
 
The heat will remain on Witty this year, but the company’s performance will be tricky to track as it completes deals to sell its oncology business to Novartis, take over the Swiss drugmaker’s vaccine unit and start up a joint venture in consumer health. Still, Witty says prospects for the company are improving as its new respiratory meds have started to pick up market share in the U.S.
 
By Eric Palmer
 

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach